HOME>CSR>Message from the Management

Message from the Management

The operating environment in the pharmaceutical industry is currently changing at a rapid pace. To maintain a position as a company that is trusted and needed by all stakeholders, Mitsubishi Tanabe Pharma aims to be a research-driven pharmaceutical company that works with a sense of speed and is the first to deliver original value. Moving forward, we will work to implement innovative, forward-looking drug discovery and to open up the future for patients and medicine. In addition, we are advancing CSR activities to contribute to the resolution of the societal issues that we confront, such as the aging of the population, growing poverty and inequality resulting from population growth, and global environmental problems.

We are taking steps in accordance with the Mitsubishi Tanabe Pharma Declaration on Corporate Citizenship, which was created in 2013. Specifically, we are actively implementing activities to contribute to the resolution of problems related to health and living environments in the countries and regions where we conduct business. We are also working to reduce the environmental burden of our business activities, based on the Environment & Safety Policy, which stipulates rules and principles for Environment & Safety activities.

Moreover, in recent years the government has led an increasingly active campaign to reform working styles. Mitsubishi Tanabe Pharma has continued to implement activities to establish a work environment that provides opportunities for active careers for diverse human resources, to reform employee working styles, and to promote employee health. These initiatives have been highly evaluated by external organizations. We have been certified under such programs as the Ministry of Economy, Trade and Industry's “Outstanding Enterprise in Health and Productivity Management ? White 500,” which recognizes companies that are implementing especially strong health and productivity management, as well as “the Eruboshi System”, which is based on the Act on Promotion of Women's Participation and Advancement in the Workplace.

Among the many issues faced by society, I believe that the Company's most important mission is to “contribute to medicine.” In August 2017, we commenced sales of Radicava in the U.S. Radicava is the first new drug in the U.S. for amyotrophic lateral sclerosis (ALS) in approximately 20 years. Patients have been eagerly awaiting Radicava, and to contribute to the treatment of as many patients as possible, we will not only provide this drug but also implement a variety of initiatives to support pharmaceutical accessibility.

The Mitsubishi Tanabe Pharma Group's philosophy states that “We contribute to the healthier lives of people around the world through the creation of pharmaceuticals,” and our vision expresses that “We strive to be a global research-driven pharmaceutical company that is trusted by society.” Moving forward, we will continue striving to realize this philosophy and vision.

Mitsubishi Tanabe Pharma
President & Representative Director

CSR

CSR
Activities
Report
2017

CSR Activities Report 2017

PDF Download

Mitsubishi
Tanabe
Pharma
Corporate
Report
2017

Corporate Report 2017

PDF Download

ReadSpeaker docReader makes documents accessible to all users including users with vision problems letting users view and listen to texts.
User guide